Ovarian Dysgerminomas Questions & Answers

1. Euscher ED. Germ cell tumors of the female genital tract. Surg Pathol Clin. 2019 Jun. 12 (2):621-49. [QxMD MEDLINE Link].

2. Iacobelli JF, Charles AK, Crook M, Stewart CJ. NUT protein immunoreactivity in ovarian germ cell tumours. Pathology. 2015 Feb. 47(2):118-22. [QxMD MEDLINE Link].

3. Bandala-Jacques A, Estrada-Rivera F, Cantu D, Prada D, Montalvo-Esquivel G, González-Enciso A, et al. Role of optimal cytoreduction in patients with dysgerminoma. Int J Gynecol Cancer. 2019 Nov. 29 (9):1405-10. [QxMD MEDLINE Link].

4. Lopes da Silva J, Luiz Renna N Jr, Paulino E, de Melo AC. Outcomes of ovarian germ cell tumors: ten years of experience at the Brazilian National Cancer Institute. Int J Gynecol Cancer. 2015 Jun. 25 (5):786-91. [QxMD MEDLINE Link].

5. Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006 May. 107 (5):1075-85. [QxMD MEDLINE Link].

6. Gimelli S, Beri S, Drabkin HA, et al. The tumor suppressor gene TRC8/RNF139 is disrupted by a constitutional balanced translocation t(8;22)(q24.13;q11.21) in a young girl with dysgerminoma. Molecular Cancer. 2009. 8:52-. [QxMD MEDLINE Link]. [Full Text].

7. Solheim O, Gershenson DM, Trope CG, et al. Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010). Eur J Cancer. 2014 Jul. 50(11):1942-50. [QxMD MEDLINE Link].

8. Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Jul 1. 25(19):2792-7. [QxMD MEDLINE Link].

9. Weinberg LE, Lurain JR, Singh DK, Schink JC. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol. 2011 May 1. 121(2):285-9. [QxMD MEDLINE Link].

10. Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol. 1990 Apr. 8(4):715-20. [QxMD MEDLINE Link].

11. Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol. 2004 Dec. 95(3):496-9. [QxMD MEDLINE Link].

12. Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, et al. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?. Gynecol Oncol. 2018 Aug. 150 (2):253-60. [QxMD MEDLINE Link].

13. De Palo G, Lattuada A, Kenda R, Musumeci R, Zanini M, Pilotti S, et al. Germ cell tumors of the ovary: the experience of the National Cancer Institute of Milan. I. Dysgerminoma. Int J Radiat Oncol Biol Phys. 1987 Jun. 13(6):853-60. [QxMD MEDLINE Link].

14. Nasioudis D, Frey MK, Chapman-Davis E, Caputo TA, Holcomb K. Fertility-preserving surgery for advanced stage ovarian germ cell tumors. Gynecol Oncol. 2017 Dec. 147 (3):493-96. [QxMD MEDLINE Link].

15. Mangili G, Sigismondi C, Lorusso D, et al. Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. Gynecol Oncol. 2011 May 1. 121(2):280-4. [QxMD MEDLINE Link].

16. Gershenson DM, Copeland LJ, del Junco G. Second-look laparotomy in the management of malignant germ cell tumors of the ovary. Obstet Gynecol. 1986 Jun. 67(6):789-93. [QxMD MEDLINE Link].

17. American College of Obstetrics and Gynecology. Educational bulletin: Ovarian Cancer. ACOG compendium of selected publications. No 250. 2000:667-75.

18. Harvey RA, Champe PC, Mycek MJ. Anticancer drugs. Lippincott's Illustrated Reviews: Pharmacology. Baltimore, Md: Lippincott Williams & Wilkins; 1992. 337-60.

19. Kumar, V Abbas AK, Fausto N, Aster J, eds. Female genital tract. Robbins Pathologic Basis of Disease. 8th ed. Elsevier Health Sciences; 2009.

20. Matei DE, Russell AH, Horowitz CJ. Ovarian germ cell tumors. In: Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME, eds. Principles and Practice of Gynecologic Oncology. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005. 989-1010.

21. Van Nagell JR, Gershenson DM. Ovarian cancer: etiology, screening, and surgery. In: Rock JA, Jones HW, eds. Telinde's Operative Gynecology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008. 1307-39.

Chad M Michener, MD Associate Professor of Surgery, Cleveland Clinic Lerner College of Medicine; Vice Chair, Department of Obstetrics and Gynecology, Main Campus, Division of Gynecologic Oncology, Obstetrics, Gynecology and Women's Health Institute, Cleveland Clinic

Chad M Michener, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Society of Gynecologic Oncology

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: MediBeacon<br/>investor for: Medasync.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Michel E Rivlin, MD Former Professor, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine

Michel E Rivlin, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Mississippi State Medical Association, Royal College of Surgeons of Edinburgh, Royal College of Obstetricians and Gynaecologists

Disclosure: Nothing to disclose.

Warner K Huh, MD Professor, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Senior Scientist, Comprehensive Cancer Center, University of Alabama School of Medicine

Warner K Huh, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American College of Surgeons, Massachusetts Medical Society, Society of Gynecologic Oncology, American Society of Clinical Oncology

Disclosure: I have received consulting fees for: Merck; THEVAX.

Allan Y Wu, MD Director, The Midwest Women's Specialty Group; Adjunct Clinical Professor, Department of Molecular Biology, The Terre Haute Center for Medical Education, Indiana University School of Medicine

Allan Y Wu, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article